Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Recurrent Glioblastoma
Interventions
Pembrolizumab, Optune GIO®, NeuroBlate®
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Conditions
Primary Brain Tumor
Interventions
NeuroBlate® System Therapy
Procedure
Lead sponsor
Monteris Medical
Industry
Eligibility
Not listed
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
New Haven, Connecticut • Kansas City, Kansas • Kansas City, Missouri + 5 more
Terminated Not applicable Interventional Results available

Feasibility Study on LITT for Medical Refractory Epilepsy

NCT02820740
Conditions
Epilepsy
Interventions
NeuroBlate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Kansas City, Kansas + 2 more
Conditions
Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
Interventions
Radiation Therapy, Steroid Therapy, Laser Interstitial Thermal Therapy
Procedure · Drug
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
Conditions
Malignant Glioma
Interventions
MK-3475, MRI-guided laser ablation
Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Gainesville, Florida • St Louis, Missouri
Completed No phase listed Observational Results available

Laser Ablation After Stereotactic Radiosurgery

NCT01651078
Conditions
Metastatic Brain Tumors, Progression, Radiation Necrosis, Quality of Life
Interventions
Not listed
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
New Haven, Connecticut • Kansas City, Kansas • St Louis, Missouri + 4 more
Conditions
Brain Tumor
Interventions
Laser Interstitial Thermotherapy (LITT)
Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
1 Year to 22 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Malignant Glioma of Brain, Glioblastoma
Interventions
Palliative regimen consisting of LITT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
Interventions
NeuroBlate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
Not listed
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 20 more
Completed No phase listed Observational Results available

PatiEnt Neuropsychological outcomeS After laseR Ablation

NCT05075850
Conditions
Cognitive Change
Interventions
Neuroblate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
16 Years and older
Enrollment
81 participants
Timeline
2021 – 2023
U.S. locations
7
States / cities
Little Rock, Arkansas • Orlando, Florida • Kansas City, Kansas + 3 more
Conditions
Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
Interventions
LITT + Pembrolizumab
Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Conditions
Glioblastoma
Interventions
NeuroBlate System, Radiation therapy and temozolomide
Device · Drug
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
St Louis, Missouri • Winston-Salem, North Carolina • Cleveland, Ohio + 1 more